Extracellular signal-regulated kinase sequences and methods of production and use
AssigneeMax-Planck-Gesellschaft zur Forderung der Wissenschaften
InventorsCornelia Lechner, Niels Peter Moller, Axel Ullrich
Life of this patent
Estimating the term…
Loading patent…
AssigneeMax-Planck-Gesellschaft zur Forderung der Wissenschaften
InventorsCornelia Lechner, Niels Peter Moller, Axel Ullrich
Estimating the term…
The present invention relates, in general, to an extracellular signal regulated kinase, ERK-5. In particular, the present invention relates to nucleic acid molecules coding for ERK-5; ERK-5 polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antisense ERK-5 nucleic acid constructs; antibodies having binding affinity to an ERK-5 polypeptide; hybridomes containing the antibodies; nucleic acid probes for the detecting of ERK-5 nucleic acid; a method of detecting ERK-5 nucleic acid or polypeptide in a sample; kits containing nucleic acid probes or antibodies; a method of detecting a compound capable of binding to ERK-5 or a fragment thereof; a method of detecting an agonist or antagonist of ERK-5 activity; a method of agonizing or antagonizing ERK-5 associated activity in a mammal; a method of treating diabetes mellitus, skeletal muscle diseases, Alzheimer's disease, or peripheral neuropathies in a mammal with an agonist or antagonist of ERK-5 activity; and a pharmaceutical composition comprising an ERK-5 agonist or antagonist.
An isolated, enriched or purified polypeptide comprising an amino acid sequence corresponding to at least 9 contiguous amino acids of SEQ. ID. NO. 2.
An organism or cell that contains a recombinant nucleic acid molecule comprising, 5′ to 3′, a promoter effective to initiate transcription in a host cell and a nucleic acid sequence encoding at least 9 contiguous amino acids of SEQ. ID. NO. 2.
An organism or cell that contains a recombinant nucleic acid molecule comprising a transcriptional region functional in a cell, a sequence complimentary to an RNA sequence encoding at least 9 amino acids of SEQ. ID. NO. 2, and a transcriptional termination region functional in said cell.
An antibody having a detectably stronger binding affinity to a polypeptide comprising at least 9 contiguous amino acids of SEQ. ID. NO. 2, than to a polypeptide comprising 9 or more contiguous amino acids of ERK-1, ERK-2, ERK-3, or ERK-4.
A method of detecting a compound capable of binding to a polypeptide comprising at least 9 contiguous amino acids of SEQ. ID. NO. 2 comprising the steps of incubating the compound with said polypeptide and detecting the presence of the compound bound to said polypeptide.
A method of detecting an agonist or antagonist of ERK-5 activity comprising incubating cells that produce ERK-5 in the presence of a compound and detecting changes in the level of ERK-5 activity.
A method of agonizing or antagonizing ERK-5 associated activity in a mammal comprising administering to said mammal an agonist or antagonist to ERK-5 in an amount sufficient to effect said agonism or antagonism.
A pharmaceutical composition comprising an ERK-5 agonist or antagonist in an amount sufficient to alter ERK-5 associated activity, and a pharmaceutically acceptable diluent, carrier, or excipient.
A method of screening for an agent useful in treating a disorder characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway involves the interaction between ERK-5 and an ERK-5 binding partner, comprising the step of assaying potential agents for those able to disrupt or promote said interaction as an indication of a useful said agent.
A method of diagnosing a disorder characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway involved the interaction between ERK-5 and an ERK-5 binding partner, comprising the step of detecting the level of said interaction as an indication of said disorder.
A method of treating a disorder characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway involved the interaction between ERK-5 and an ERK-5 binding partner, comprising the step of disrupting or promoting said interaction in vivo.
The method of claim 20 wherein said disorder is a muscle cell differentiation disorder.
The method of claim 21 wherein said muscle cell differentiation disorder is a muscular dystrophy.
Dependencies are inferred from the claim text.